MAP2K7 and cancer: BRAF-induced MAPK-ERK activation may not be controlled with MEK inhibition only, and may require combined MEK and BRAF inhibition, whereas the MAPK-ERK activation can be modulated with MEK inhibition alone more readily in RAS-mutation-initiated cancers [33,34,35] (Figure 1).